Intersect ENT Inc. (NASDAQ:XENT) shares shot up 3.1% during mid-day trading on Tuesday . The company traded as high as $15.70 and last traded at $15.53, with a volume of 185,525 shares. The stock had previously closed at $15.06.

A number of research firms have issued reports on XENT. Canaccord Genuity reaffirmed a “buy” rating and issued a $20.00 price target on shares of Intersect ENT in a report on Thursday, August 4th. BTIG Research began coverage on shares of Intersect ENT in a report on Tuesday, July 12th. They issued a “neutral” rating for the company. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Intersect ENT in a report on Wednesday, August 3rd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $24.20.

The firm’s 50-day moving average price is $14.88 and its 200-day moving average price is $15.97. The stock’s market capitalization is $441.32 million.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. The firm had revenue of $19.30 million for the quarter, compared to analyst estimates of $18.91 million. The company’s revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) EPS. Equities analysts expect that Intersect ENT Inc. will post ($0.96) EPS for the current fiscal year.

In other Intersect ENT news, VP James Stambaugh sold 3,977 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $17.00, for a total transaction of $67,609.00. Following the completion of the transaction, the vice president now owns 27,977 shares in the company, valued at approximately $475,609. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

A hedge fund recently raised its stake in Intersect ENT stock. RS Investment Management Co. LLC boosted its stake in Intersect ENT Inc. (NASDAQ:XENT) by 68.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,328,250 shares of the company’s stock after buying an additional 538,720 shares during the period. RS Investment Management Co. LLC owned about 4.74% of Intersect ENT worth $29,886,000 at the end of the most recent quarter.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.